Auscann Group Holdings Ltd
ASX:AC8

Watchlist Manager
Auscann Group Holdings Ltd Logo
Auscann Group Holdings Ltd
ASX:AC8
Watchlist
Price: 0.04 AUD -4.76% Market Closed
Market Cap: AU$17.6m

Net Margin

-471.4%
Current
Improving
by 297.7%
vs 3-y average of -769.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-471.4%
=
Net Income
AU$-9.7m
/
Revenue
AU$2m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-471.4%
=
Net Income
AU$-9.7m
/
Revenue
AU$2m

Peer Comparison

Country Company Market Cap Net
Margin
AU
Auscann Group Holdings Ltd
ASX:AC8
17.6m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

In line with most companies in Australia
Percentile
31st
Based on 4 004 companies
31st percentile
-471.4%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Auscann Group Holdings Ltd
Glance View

Market Cap
17.6m AUD
Industry
Pharmaceuticals

AusCann Group Holdings Ltd. engages in development, production, and distribution of cannabinoid-based medicines within Australia and internationally. The company is headquartered in Perth, Western Australia. The firm focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.

AC8 Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-471.4%
=
Net Income
AU$-9.7m
/
Revenue
AU$2m
What is Auscann Group Holdings Ltd's current Net Margin?

The current Net Margin for Auscann Group Holdings Ltd is -471.4%, which is above its 3-year median of -769.1%.

How has Net Margin changed over time?

Over the last 3 years, Auscann Group Holdings Ltd’s Net Margin has increased from -3 422.1% to -471.4%. During this period, it reached a low of -3 422.1% on Dec 1, 2020 and a high of -471.4% on Jan 31, 2024.

Back to Top